AOD 9604 vs semaglutide
These two drugs are not in the same league for weight loss — but that doesn't make the comparison pointless. Here's the honest side-by-side of AOD 9604 versus semaglutide on mechanism, efficacy, side effects, and real-world fit.
- Semaglutide produces ~15% average body weight loss at 68 weeks (STEP-1 trial). AOD 9604 produced ~2.6 kg at 12 weeks in its Phase IIb.
- Semaglutide works through appetite suppression; AOD 9604 works through lipolysis. The mechanisms don't overlap.
- Semaglutide's side effect profile is dominated by GI effects (nausea, constipation); AOD 9604 has no GI signature.
- Semaglutide is FDA-approved and available with a prescription. AOD 9604 is not FDA-approved.
- For pure weight loss, semaglutide wins decisively. For targeted fat loss without appetite change, AOD 9604 is a more specialized tool.
The short version
AOD 9604 and semaglutide both get classified as "weight loss peptides," but the comparison is unfair in almost every dimension. Semaglutide is an FDA-approved GLP-1 agonist with hundreds of thousands of patients on it, a massive clinical trial record, and a 15% average weight loss in the STEP-1 trial. AOD 9604 is an investigational growth hormone fragment that didn't hit its primary endpoint in Phase IIb and was never approved.
For pure weight loss magnitude, semaglutide wins by a wide margin. But the two drugs have completely different mechanisms and completely different side effect profiles, which means there are scenarios where the comparison is more nuanced than raw efficacy would suggest.
Side-by-side comparison
| Feature | AOD 9604 | Semaglutide |
|---|---|---|
| Drug class | hGH fragment (176–191) | GLP-1 receptor agonist |
| Mechanism | Stimulates lipolysis; inhibits lipogenesis | Suppresses appetite; slows gastric emptying |
| Route | Subcutaneous or oral (poor bioavailability) | Subcutaneous weekly or oral daily |
| Half-life | ~38 minutes | ~7 days |
| Typical dosing | 300 mcg daily (injection) | 0.25 → 2.4 mg weekly (subcutaneous) |
| Avg clinical weight loss | ~2.6 kg at 12 weeks (Phase IIb) | ~15% body weight at 68 weeks (STEP-1) |
| Primary side effects | Mild headache, injection site redness | Nausea, vomiting, constipation, fatigue |
| GI side effects | Minimal | Substantial |
| Appetite effect | None | Significant suppression |
| Muscle preservation | Preserved in studies | ~25–39% of lost weight is lean mass |
| FDA approval | No | Yes (Wegovy, Ozempic) |
| Cost (cash, U.S.) | Gray market only | ~$1,000–$1,350/month retail |
Mechanism: why these drugs are not interchangeable
Semaglutide's weight loss comes almost entirely from appetite suppression and slowed gastric emptying. It tells the brain you're full, and it physically slows how fast food leaves the stomach. Patients on semaglutide eat less, often dramatically less, and the weight loss follows from the caloric deficit the drug creates.
AOD 9604 does none of that. It does not act on the brain's appetite centers, does not affect gastric emptying, and does not change hunger signaling. What it does is directly stimulate fat cells to release their stored triglycerides — a metabolic mechanism rather than a behavioral one. The resulting weight loss is smaller because stimulating lipolysis without creating a parallel caloric deficit has limited impact: the mobilized fatty acids can be re-esterified back into triglycerides if energy intake remains high.
Side effects: where AOD 9604 has an advantage
The GI side effects of semaglutide are its biggest limitation in practice. Nausea affects roughly 40–45% of patients, vomiting 15–25%, and constipation 20–25%. Most of these are mild and improve after the initial titration, but they are the main reason patients discontinue treatment. Semaglutide is also associated with fatigue, muscle loss (a significant fraction of the weight lost), and — at higher doses — gallbladder issues.
AOD 9604's clinical side effect profile is much cleaner. No GI signature, no measurable muscle loss, no effect on IGF-1 or insulin sensitivity, no appetite suppression to contend with. The tradeoff is that the efficacy is also much smaller. For someone who cannot tolerate GLP-1 side effects, or who specifically wants to preserve lean mass during a cut, AOD 9604 becomes an actual option rather than a rounding error.
Semaglutide and AOD 9604 together
The combination of semaglutide and AOD 9604 is occasionally discussed in peptide communities as a way to combine appetite suppression with direct lipolysis. There are no clinical trials of this combination and no published safety data. Theoretically the mechanisms do not conflict — one acts centrally on appetite, the other peripherally on adipocytes — but "no obvious conflict" is not the same as "safe and effective." Anyone considering a stack like this should do it under medical supervision, not from peptide forums.
Which drug is the right fit?
- Choose semaglutide if your primary goal is substantial weight loss, you can tolerate the GI side effects, and you have access to a prescription.
- Consider AOD 9604 if your goal is targeted fat loss in a specific depot (abdominal), you are already lean-ish and want to avoid muscle loss, and you cannot or do not want appetite suppression as a mechanism.
- Neither is appropriate if you have not first addressed the fundamentals: a sustainable caloric deficit, protein intake adequate to preserve lean mass, and consistent resistance training.
For the comparison against tirzepatide, which produces even larger weight loss than semaglutide in trials, see the AOD 9604 vs tirzepatide page.
Frequently asked questions
Is AOD 9604 better than semaglutide?
No, not for weight loss magnitude. Semaglutide produces roughly 15% body weight loss at 68 weeks; AOD 9604 produced ~2.6 kg at 12 weeks in its clinical trial. AOD 9604 has a cleaner side effect profile but is a much weaker weight loss drug.
Can you take AOD 9604 and semaglutide together?
Some peptide communities discuss this stack, but there are no clinical trials or published safety data on the combination. The mechanisms do not obviously conflict, but that is not the same as being validated. Anyone considering this should do it under medical supervision.
Which has worse side effects, AOD 9604 or semaglutide?
Semaglutide has a substantially worse side effect profile, dominated by GI symptoms (nausea, vomiting, constipation) and measurable muscle loss. AOD 9604's clinical side effect profile is minimal.
Why doesn't AOD 9604 produce weight loss like semaglutide?
Different mechanism. Semaglutide works by suppressing appetite, which directly reduces calorie intake. AOD 9604 stimulates fat breakdown but does not affect appetite, so without a dietary caloric deficit the effect on scale weight is small.
Is AOD 9604 cheaper than semaglutide?
Not through legitimate channels. Semaglutide is FDA-approved and available through pharmacies (with insurance, often for a small copay; cash retail ~$1,000–$1,350/month). AOD 9604 is not FDA-approved and has no legitimate U.S. prescription source.